CNM-Au8 Emerging Drug Insight and Market Forecast - 2032

“CNM-Au8 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about CNM-Au8 for Amyotrophic Lateral Sclerosis in seven major markets. A detailed picture of the CNM-Au8 for Amyotrophic Lateral Sclerosis in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the CNM-Au8 for Amyotrophic Lateral Sclerosis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CNM-Au8 market forecast analysis for Amyotrophic Lateral Sclerosis in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary

CNM-Au8 is a concentrated, aqueous suspension of clean surfaced faceted nanocrystalline gold (Au) that acts catalytically to support various intracellular biological reactions. The drug consists solely of gold atoms organized into faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water and is produced utilizing a patented electro-crystal-chemistry. Preclinical studies of CNM-Au8 demonstrated that the drug protects motor neurons from death through a novel nano catalytic mechanism, increasing the body's ability to resist several stressors associated with this disease.

The foundational role of the drug is to act as a therapeutic nanocatalyst that can treat impaired bioenergetics within diseased or damaged cells and may also have broad applications in other disease areas. By donating and/or receiving electrons as needed, the neuro-therapeutic CNM-Au8, increases cellular energy reserves while independently decreasing harmful reactive molecules through direct catalytic activity. Nanocatalysis can improve the survival and function of neurons in addition to supporting oligodendrocytes' ability to create new myelin.

CNM-Au8 has received regulatory approval to proceed to clinical studies for the treatment of multiple sclerosis remyelination failure and neuro-protection of Amyotrophic Lateral Sclerosis and Parkinson's disease. It was selected as one of the first drug regimens to be evaluated as an Amyotrophic Lateral Sclerosis treatment in the HEALEY Amyotrophic Lateral Sclerosis Platform Trial by a panel of expert Amyotrophic Lateral Sclerosis scientists.

The company is currently conducting a Phase II/III and a Phase II trial (REPAIR-Amyotrophic Lateral Sclerosis) of the gold nanocrystals (CNM-Au8) in patients with Amyotrophic Lateral Sclerosis. The company anticipated presenting additional data from its REPAIR-Amyotrophic Lateral Sclerosis trial in the second half of 2020. In November 2021, the company announced the complete enrollment of patients in the HEALEY Amyotrophic Lateral Sclerosis Platform Trial, and results are expected in the second half of 2022.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the CNM-Au8 description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.
• Elaborated details on CNM-Au8 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CNM-Au8 research and development activities in Amyotrophic Lateral Sclerosis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CNM-Au8.
• The report contains forecasted sales of CNM-Au8 for Amyotrophic lateral sclerosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.
• The report also features the SWOT analysis with analyst views for CNM-Au8 in Amyotrophic Lateral Sclerosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CNM-Au8 Analytical Perspective

In-depth CNM-Au8 Market Assessment

This report provides a detailed market assessment of CNM-Au8 for Amyotrophic lateral sclerosis in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

CNM-Au8 Clinical Assessment

The report provides the clinical trials information of CNM-Au8 for Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Amyotrophic lateral sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CNM-Au8 dominance.
• Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to CNM-Au8 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CNM-Au8 in Amyotrophic Lateral Sclerosis.
• Our in-depth analysis of the forecasted sales data of CNM-Au8 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CNM-Au8 in Amyotrophic Lateral Sclerosis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of CNM-Au8?
• What is the clinical trial status of the study related to CNM-Au8 in Amyotrophic lateral sclerosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CNM-Au8 development?
• What are the key designations that have been granted to CNM-Au8 for Amyotrophic Lateral Sclerosis?
• What is the forecasted market scenario of CNM-Au8 for Amyotrophic Lateral Sclerosis?
• What are the forecasted sales of CNM-Au8 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to CNM-Au8 for Amyotrophic Lateral Sclerosis?
• Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?